Lupus nephritis is a potentially life-threatening manifestation of systemic lupus erythematosus, an autoimmune disease that commonly affects the kidneys.1 It affects approximately 1.7 million people worldwide and has a profound impact on their lives and outlook, with up to a third of people progressing to end-stage kidney disease within 10 years, where the only options are dialysis or transplant.2-4
Currently, there is no cure.1
Applying our long-standing expertise in immunology, we want to deliver meaningful innovation that addresses unmet needs, importantly aiming to prevent or delay progression to end-stage kidney disease. This includes working closely with the lupus nephritis community, who are predominantly women and of colour - traditionally underrepresented in drug development - to understand and break down the barriers they face.5
References
Hocaoglu M, et al. Incidence, Prevalence, and Mortality of Lupus Nephritis: A Population-Based Study Over Four Decades—The Lupus Midwest Network (LUMEN). Arthritis Rheumatol. 2023;75(4): 567-573.
Tian J, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82:351-56
Hoi A, et al. Systemic lupus erythematosus. The Lancet. 2024;403(10441):2326-2338
Mok C, et al. Treatment of lupus nephritis: consensus evidence and perspectives. Natures reviews rheumatology. 2023;19:227-238
Parikh SV, et al. Update on Lupus Nephritis: Core Curriculum 2020. Am J Kidney Dis. 2020;76:265-28
Dr Ioannis Parodis on important considerations when caring for patients with lupus nephritis.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.